IL320544A - פורמולציות תרופתיות דרך הפה המכילות 4-((2-hydroxy-3-methoxybenzyl)amino) נגזרות בנזן-סולפונאמיד - Google Patents

פורמולציות תרופתיות דרך הפה המכילות 4-((2-hydroxy-3-methoxybenzyl)amino) נגזרות בנזן-סולפונאמיד

Info

Publication number
IL320544A
IL320544A IL320544A IL32054425A IL320544A IL 320544 A IL320544 A IL 320544A IL 320544 A IL320544 A IL 320544A IL 32054425 A IL32054425 A IL 32054425A IL 320544 A IL320544 A IL 320544A
Authority
IL
Israel
Prior art keywords
methoxybenzyl
hydroxy
amino
pharmaceutical formulations
formulations containing
Prior art date
Application number
IL320544A
Other languages
English (en)
Inventor
David Maloney
Henry Flanner
Matthew Boxer
Original Assignee
Veralox Therapeutics Inc
David Maloney
Henry Flanner
Matthew Boxer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Veralox Therapeutics Inc, David Maloney, Henry Flanner, Matthew Boxer filed Critical Veralox Therapeutics Inc
Publication of IL320544A publication Critical patent/IL320544A/he

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
IL320544A 2022-11-02 2023-11-02 פורמולציות תרופתיות דרך הפה המכילות 4-((2-hydroxy-3-methoxybenzyl)amino) נגזרות בנזן-סולפונאמיד IL320544A (he)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202263382032P 2022-11-02 2022-11-02
PCT/US2023/078471 WO2024097846A1 (en) 2022-11-02 2023-11-02 Oral pharmaceutical formulations containing 4-((2-hydroxy-3-methoxybenzyl)amino) benzenesulfonamide derivatives

Publications (1)

Publication Number Publication Date
IL320544A true IL320544A (he) 2025-06-01

Family

ID=90931549

Family Applications (1)

Application Number Title Priority Date Filing Date
IL320544A IL320544A (he) 2022-11-02 2023-11-02 פורמולציות תרופתיות דרך הפה המכילות 4-((2-hydroxy-3-methoxybenzyl)amino) נגזרות בנזן-סולפונאמיד

Country Status (8)

Country Link
EP (1) EP4612135A1 (he)
JP (1) JP2025535509A (he)
KR (1) KR20250099148A (he)
CN (1) CN120435464A (he)
AU (1) AU2023372568A1 (he)
IL (1) IL320544A (he)
MX (1) MX2025005061A (he)
WO (1) WO2024097846A1 (he)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025207887A1 (en) * 2024-03-27 2025-10-02 Veralox Therapeutics Inc. Methods for treating heparin-induced thrombocytopenia

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3036226B1 (en) * 2013-08-22 2020-01-08 The General Hospital Corporation Inhibitors of human 12/15-lipoxygenase
ES2968371T3 (es) * 2013-10-10 2024-05-09 Eastern Virginia Medical School Derivados de 4-((2-hidroxi-3-metoxibencil)amino) bencenosulfonamida como inhibidores de la 12-lipoxigenasa
CN116370407A (zh) * 2021-12-22 2023-07-04 维拉洛斯治疗公司 包含4-((2-羟基-3-甲氧基苯甲醇)氨基)苯磺酰胺衍生物的水性肠道外药物制剂

Also Published As

Publication number Publication date
AU2023372568A1 (en) 2025-05-15
JP2025535509A (ja) 2025-10-24
EP4612135A1 (en) 2025-09-10
MX2025005061A (es) 2025-06-02
KR20250099148A (ko) 2025-07-01
WO2024097846A1 (en) 2024-05-10
CN120435464A (zh) 2025-08-05

Similar Documents

Publication Publication Date Title
PL370292A1 (en) Formulations for oral administration of active compounds
AU2003229555A1 (en) Oral administration form for difficulty soluble basic active ingredients which are applied orally
NO20033732L (no) N-substituerte ikke-aryl-heterosykliske NMDA/NR2B-antagonister, og farmasoytiske preparater som omfatter slike forbindelser.
SG147450A1 (en) Sustained release pharmaceutical compositions comprising aplindore and derivatives thereof
CY1114803T1 (el) Παραγωγα πυριμιδινο σουλφοναμιδιου ως ρυθμιστες υποδοχεων χημειοκινης
NO20080220L (no) Formuleringer med hoy medikament belastning og doseringsformer
EP4516353A3 (en) Pharmaceutical compositions comprising (2s)-{(1s)-1-cyano-2-[4-(3-methyl-2-oxo-2,3-dihydro-1,3-benzoxazol-5-yl)phenyl]ethyl}-1,4-oxazepane-2-carboxamide
CY1113462T1 (el) Μορφη δοσολογιας περιεχουσα παντοπραζολη ως δραστικο συστατικο
NO20033343L (no) Farmasöytiske doseringsformer av epothiloner for oral administrasjon
PA8580601A1 (es) Composicion farmaceutica de altas dosis
BR112023026909A2 (pt) Sal farmaceuticamente aceitável de ap1189 ((e)-n-[1-(2-nitrofenil)-1-h-pirrol-2-il-alilidenoamino]-guanidina), composição farmacêutica, forma de dosagem única, e, formulação oral
EP4188329A4 (en) PHARMACEUTICAL FORMULATIONS CONTAINING TADALAFIL
IL313761A (he) פורמולציות פרמצבטיות פרנטרליות מימיות המכילות נגזרות 4-2-הידרוקסי-3-מתוקס בנזן סולפונאמיד
CA3263118A1 (en) STABLE ORAL PHARMACEUTICAL FORMULATION CONTAINING RUXOLITINIB HELIFUMARATE
CA3272561A1 (en) Oral pharmaceutical formulations containing 4-((2-hydroxy-3-methoxybenzyl)amino) benzenesulfonamide derivatives
HK40131660A (en) Oral pharmaceutical formulations containing 4-((2-hydroxy-3-methoxybenzyl)amino) benzenesulfonamide derivatives
IL321857A (he) פורמולציות rna לשימוש פרמצבטי
EP4034120A4 (en) SOLID ORAL PHARMACEUTICAL FORMULATIONS COMPRISING SAPROPTERIN DICHLORHYDRATE AND AT LEAST ONE PHARMACEUTICAL EXCIPIENT
TW201129557A (en) Pharmaceutical composition for oral administration
IL314206A (he) פורמולציה תרופתית
HK40117640A (en) Aqueous parenteral pharmaceutical formulations containing 4-((2-hydroxy-3-methoxybenzyl)amino) benzene sulfonamide derivatives
ITTO20020672A1 (it) Composizioni farmaceutiche contenenti cheto-acidi per somministrazione endoperitoneale
IL296533B2 (he) תולדות טטראזול, הכנתן ותכשירי רוקחת המכילים אותן
IL175556A0 (en) Pharmaceutical composition for oral administration of a pyrazol-3-carboxamide derivative
CA3289959A1 (en) Oral pharmaceutical compositions